人肝癌靶向性CD80基因表达重组腺病毒载体的构建及鉴定

目的:构建人肝癌靶向性CD80基因重组腺病毒载体。方法:首先,从人基因组DNA中克隆AFP增强子、启动子,利用腺病毒穿梭质粒pShuttle和pShutte-CMV,采用AFP增强子替换CMV启动子,构建含有AFP启动子和增强子的穿梭质粒,命名为pShuttle-AFP。将人CD80基因克隆到pShuttle-AFP的AFP增强子和启动子之后,构建pShuttle-AFP-CD80质粒。再将其与腺病毒骨架质粒pAdEasy-1共转化E.coliBJ5183,利用同源重组构建腺病毒质粒pAd-AFP-CD80。以获得的重组子转染AD293细胞后制备重组腺病毒,并对重组的病毒进行鉴定和病毒滴度测定。结果:测序结果与Genebank中公布的AFP启动子、核心增强子和CD80基因序列相符。双酶切结果与预期结果相符。PacI酶切结果与目的结果一致。穿梭质粒pShutte-AFP-CD80和腺病毒质粒pAd-AFP-CD80经酶切和PCR鉴定均获得期望大小的目的片段。结论:成功的构建了人肝癌靶向性pAd-AFP-CD80腺病毒载体,为CD80基因在肝癌靶向性治疗的研究奠定了基础。

Construction of Human Hepatoma-targeting Recombinant Adenovirus Vector of CD80 and Its Identification

Objective: To construct the hepatoma targeting CD80 gene recombinant adenovirus vector. Methods: The enhancer and promoter of AFP were cloned from the human genomic DNA, and pShuttle-AFP plasmid was generated by replacing the CMV promoter of pShuttle-CMV. CD80 gene was inserted into the downstream of AFP enhancer and promoter, to construct the pShuttle-AFP-CD80 plasmid. After digestion with Pme I, pShuttle-AFP-CD80 was co-transformed into E. coli BJ5183 with adenovirus backbone plasmid, and pAd-AFP-CD80 was...